A prospective open-label trial of a CBD/THC cannabis oil in dravet syndrome Blathnaid McCoy, Laura Wang, Maria Zak, Sameer Al-Mehmadi, Nadia Kabir, Kenda Alhadid, Kyla McDonald, Grace Zhang, Rohit Sharma, Robyn Whitney, Katia Sinopoli & O. Carter Snead III Annals of Clinical and Translational Neurology, 2018, 5, (9), 1077–1088 doi: 10.1002/acn3.621 Abstract Introduction : Both D9 Tetrahydrocannabidiol (THC) and cannabidiol (CBD) components of cannabis, have been shown to have anticonvulsant effects. Cannabis oils are used to treat seizures in drug-resistant epilepsy (DRE). Recent trials provide data on dosing, side effects, and efficacy of CBD, yet there is a paucity of information on THC in epilepsy. Primary [...]
Lire la suiteCannabidiol attenuates seizures and EEG abnormalities in Angelman syndrome model mice. Bin Gu, Manhua Zhu, Madison R. Glass, Marie Rougié, Viktoriya D. Nikolova, Sheryl S. Moy, Paul R. Carney, and Benjamin D. Philpot Journal of Clinical Investigation, 2019 Sep 10, pii: 130419. doi : 10.1172/JCI130419 PMID : 31503547 Abstract Angelman syndrome (AS) is a neurodevelopmental disorder characterized by intellectual disability, lack of speech, ataxia, EEG abnormalities, and epilepsy. Seizures in AS individuals are common, debilitating, and often drug-resistant. Therefore, there is an unmet need for better treatment options. Cannabidiol (CBD), a major phytocannabinoid constituent of cannabis, has antiseizure activity and behavioral benefits in preclinical and [...]
Lire la suiteEC Clears Cannabidiol for Severe Forms of Epilepsy Deborah Brauser Medscape Medical News © September 23, 2019 The European Commission (EC) has approved the add-on use of cannabidiol oral solution (Epidyolex, GW Pharmaceuticals) for treating seizures associated with two severe forms of epilepsy, the manufacturer reports. The indication for the drug in the EC's marketing authorization is for use as adjunctive therapy with clobazam (multiple brands) in patients ages 2 and older who have Lennox-Gastaut syndrome (LGS) or Dravet syndrome. As reported by Medscape Medical News, the European Medicine's Agency's (EMA's) Committee for Medicinal Products for Human Use recommended approval for the drug in July. A year earlier, [...]
Lire la suiteCannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD) ClinicalTrials.gov Identifier : NCT03202303 Recruitment Status : Not yet recruiting First Posted : June 28, 2017 Last Update Posted : April 2, 2019 https://clinicaltrials.gov/ct2/show/NCT03202303?term=cannabinoids&cond=Autism+Spectrum+Disorder&rank=2 Sponsor : Eric Hollander Collaborators : United States Department of Defense, GW Pharmaceuticals Information provided by (Responsible Party) : Eric Hollander, Montefiore Medical Center, USA Study Design Study Type : Interventional (Clinical Trial) Estimated Enrollment : 100 participants Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: Phase 2, 12-week double-blind, randomized, placebo-controlled trial Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Masking Description: Double-Blind Primary Purpose: Treatment Official Title: Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD) Estimated Study Start Date : June 2019 Estimated [...]
Lire la suite